Teicoplanin
- Generic Name
- Teicoplanin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C88H97Cl2N9O33
- CAS Number
- 61036-62-2
- Unique Ingredient Identifier
- 4U3D3YY81M
- Background
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
- Indication
For the treatment of bacterial infections caused by susceptible microorganisms.
- Associated Conditions
- Angina Pectoris, Anginal Pain, Bacteremia, Bloodstream Infections (BSI), Bone and Joint Infections, Clostridium Difficile, Clostridium Difficile Infection (CDI), Community Acquired Pneumonia (CAP), Complicated Urinary Tract Infection, Infective Endocarditis (IE), Lower Respiratory Tract and Lung Infections, Non-complicated Skin and Soft Tissue Infections, Nosocomial Pneumonia, Peritonitis, Skin and Soft Tissue Infections (SSTIs), Urinary Tract Infection
- Associated Therapies
- -
Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
- Conditions
- Skin Diseases, InfectiousSoft Tissue Infections
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 194
- Registration Number
- NCT00430937
Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
- Conditions
- Osteomyelitis
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 75
- Registration Number
- NCT00428844
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical center, Lebanon, New Hampshire, United States
🇷🇺Federal Healthcare Institute "Novosibirsk Scientific Research Institute of Traumatology and Orthopedy Rosmeditechnology", Novosibirsk, Russian Federation
🇺🇸Gundersen Clinic, LTD, La Crosse, Wisconsin, United States
A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely
- Conditions
- Staphylococcal Infections
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2006-08-24
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00368498
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.